Display options
Cite
Guo W, Nie L, Wang XR, et al. Comparison of Placebo Effect between Asian and Caucasian Type 2 Diabetic Patients: A Meta-Analysis. Chin Med J (Engl). 2018;131(13):1605-1612doi: 10.4103/0366-6999.235107.
Guo, W., Nie, L., Wang, X. R., Xu, M. L., Yang, W. J., Gao, X. Y., Cai, X. L., & Ji, L. N. (2018). Comparison of Placebo Effect between Asian and Caucasian Type 2 Diabetic Patients: A Meta-Analysis. Chinese medical journal, 131(13), 1605-1612. https://doi.org/10.4103/0366-6999.235107
Guo, Wei, et al. "Comparison of Placebo Effect between Asian and Caucasian Type 2 Diabetic Patients: A Meta-Analysis." Chinese medical journal vol. 131,13 (2018): 1605-1612. doi: https://doi.org/10.4103/0366-6999.235107
Guo W, Nie L, Wang XR, Xu ML, Yang WJ, Gao XY, Cai XL, Ji LN. Comparison of Placebo Effect between Asian and Caucasian Type 2 Diabetic Patients: A Meta-Analysis. Chin Med J (Engl). 2018 Jul 05;131(13):1605-1612. doi: 10.4103/0366-6999.235107. PMID: 29941715; PMCID: PMC6032690.
Copy Download .nbib Format: NLM
Share it on

Chin Med J (Engl). 2018 Jul 05;131(13):1605-1612. doi: 10.4103/0366-6999.235107.

Comparison of Placebo Effect between Asian and Caucasian Type 2 Diabetic Patients: A Meta-Analysis.

Chinese medical journal

Wei Guo, Lin Nie, Xi-Rui Wang, Mei-Ling Xu, Wen-Jia Yang, Xue-Ying Gao, Xiao-Ling Cai, Li-Nong Ji

Affiliations

  1. Department of Emergency, Peking University People's Hospital, Beijing 100044, China.
  2. Department of Endocrinology and Metabolism, Beijing Airport Hospital, Beijing 101318, China.
  3. Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing 100044, China.

PMID: 29941715 PMCID: PMC6032690 DOI: 10.4103/0366-6999.235107

Abstract

BACKGROUND: Placebo was defined as any therapy that is used for its nonspecific psychological and physiologic effect but has no specific pharmacologic impact on the condition being treated. Besides medication therapies, studies have found that the optimal dietary approach as well as physical activity and education are useful to control hyperglycemia in patients with type 2 diabetes (T2DM). The aim of this study was to evaluate the placebo effects of antidiabetic therapies in Asian and Caucasian T2DM patients and make a comparison between the two ethnicities.

METHODS: A search using the MEDLINE database, EMBASE, and Cochrane Database was performed, from when recording began until December 2016. The main concepts searched in English were sulfonylurea (SU); alpha glucosidase inhibitors (AGI); metformin (MET); thiazolidinediones (TZD); dipeptidyl peptidase-4 inhibitors (DPP-4i); sodium-glucose cotransporter 2 inhibitors (SGLT2i); glucagon-like peptide-1 receptor agonist (GLP-1RA); type 2 diabetes (T2DM); placebo controlled; and randomized controlled trials. Using the Cochrane instrument, we evaluated the adequacy of randomization, allocation concealment procedures, and blinding.

RESULTS: This study included 63 studies with a total of 7096 Asian patients involved and 262 studies with a total of 27,477 Caucasian patients involved. In Caucasian population, the use of placebo led to significant reductions of glycosylated hemoglobin (HbA1c), -0.683% (P = 0.008) in SU monotherapy treatment, -0.193% (P = 0.001) in DPP-4i treatment, and -0.230% (P < 0.001) in SGLT2i treatment, respectively. In Asian population, the use of placebo resulted in significant decreases of HbA1c, -0.162% (P = 0.012) in DPP-4i treatment and -0.269% (P = 0.028) in GLP-1RA add-on therapy, respectively. The placebo also significantly reduced body weight. In Caucasian population, placebo use resulted in 0.833 kg (P = 0.006) weight loss by SU treatment and 0.953 kg (P = 0.006) weight loss by GLP-1RA treatment. In Asian population, the placebo led to a weight change of 0.612 kg (P < 0.001) by GLP-1RA analog treatment. The changes of HbA1c and weight due to the placebo effect in other treatments were not significant in both Asian and Caucasian population. Comparisons of the placebo effect on HbA1c change and weight change in each treatment group indicated that no significant difference was found between Asian and Caucasian population.

CONCLUSIONS: The overall differences of the placebo effect on HbA1c changes as well as on body weight changes were not significant between Asian and Caucasian T2DM patients. The placebo effect on HbA1c changes and weight changes was not associated with baseline age, gender, baseline body mass index, baseline HbA1c, duration of diabetes, or study duration.

Keywords: Asian; Caucasian; Placebo; Type 2 Diabetes Mellitus

Conflict of interest statement

There are no conflicts of interest

References

  1. Cochrane Database Syst Rev. 2006 Jul 19;(3):CD002968 - PubMed
  2. JAMA. 2009 May 27;301(20):2129-40 - PubMed
  3. Cochrane Database Syst Rev. 2004;(3):CD003974 - PubMed
  4. N Engl J Med. 2015 Jul 2;373(1):8-9 - PubMed
  5. J Diabetes. 2015 May;7(3):347-59 - PubMed
  6. Psychiatr Q. 1968;42(4):653-95 - PubMed
  7. PLoS One. 2013 Nov 13;8(11):e79421 - PubMed
  8. Lancet. 2010 Jan 30;375(9712):408-18 - PubMed
  9. N Engl J Med. 2010 Mar 25;362(12):1090-101 - PubMed
  10. Curr Diab Rep. 2012 Dec;12(6):686-96 - PubMed
  11. J Am Diet Assoc. 2010 Dec;110(12):1852-89 - PubMed
  12. Am J Med. 2013 Oct;126(10):925.e11-22 - PubMed
  13. Ann Intern Med. 1977 May;86(5):626-36 - PubMed
  14. Diabetologia. 2013 Apr;56(4):696-708 - PubMed
  15. J Am Diet Assoc. 2008 Apr;108(4 Suppl 1):S52-8 - PubMed
  16. J Clin Epidemiol. 2009 Oct;62(10):e1-34 - PubMed
  17. Am J Hypertens. 2001 Jun;14(6 Pt 1):546-52 - PubMed
  18. Epilepsia Open. 2016 Jul 27;1(1-2):9-21 - PubMed
  19. JAMA. 2011 May 4;305(17):1790-9 - PubMed
  20. Diabetes Care. 2006 Nov;29(11):2518-27 - PubMed
  21. BMJ. 2011 Oct 18;343:d5928 - PubMed
  22. Can Med Assoc J. 1983 Apr 15;128(8):921-5 - PubMed
  23. Am J Clin Nutr. 2013 Mar;97(3):505-16 - PubMed
  24. Ann N Y Acad Sci. 2013 Apr;1281:64-91 - PubMed

Substances

MeSH terms

Publication Types